نوع مقاله : Review Article
نویسندگان
1 گروه علوم تغذیه، دانشکده علوم تغذیه و صنایع غذایی، دانشگاه علوم پزشکی کرمانشاه، کرمانشاه، ایران.
2 کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران.
3 کمیته تحقیقات دانشجویی، دانشگاه علوم پزشکی کرمانشاه، کرمانشاه، ایران.
4 Department of Nutritional Sciences, School of Nutritional Sciences and Food Technology, Kermanshah University of Medical Sciences, Kermanshah, Iran.
چکیده
تازه های تحقیق
مریم شریفی: PubMed, Google Scholar
جلال مولودی: Google Scholar
صادق مظاهری-تهرانی: Google Scholar
کلیدواژهها
موضوعات
عنوان مقاله [English]
نویسندگان [English]
Introduction: Type 2 Diabetes Mellitus (T2DM) is a prevalent chronic disease affecting adults worldwide. Recent advancements in its management have been marked by the introduction of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and non-injectable therapies, which offer significant benefits for glycemic control and the management of associated metabolic comorbidities. Inconsistent findings from randomized controlled trials (RCTs) on the effects of GLP-1 RAs on HbA1c and weight loss in T2DM patients necessitate a systematic review to synthesize and critically assess the cumulative evidence.
Materials & Methods: We conducted a strategic search of PubMed, Scopus, Embase, ProQuest, and Google Scholar databases from inception to January 2025. The inclusion criteria were all RCTs in English‐language journals on T2DM that were intervened with GLP-1 RAs. We applied the Critical Appraisal Skills Program (CASP) checklist to assess the quality of included articles.
Results: Out of 574 articles reviewed, only 17 met the eligibility criteria. The findings of this study indicate that Tirzepatide has the most effective role in reducing HbA1c and fasting plasma glucose concentrations (MD -1.50%, and -3.19 mmol/L), while CagriSema resulted in the highest weight loss (MD -4.73 kg) among the other kinds of GLP-1 Ras in T2DM patients. Nevertheless, the majority of trials highlighted gastrointestinal risks associated with GLP-1Ras, emphasizing the need for safety, particularly with high-dose regimens.
Conclusion: The beneficial effect of GLP-1Ras on glycemia and weight loss positions them as first-line therapies for individuals with obesity and T2DM. However, further trials are needed to determine optimal dosing and duration.
کلیدواژهها [English]
)